Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “capecitabine” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 38
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 38 pipeline programs matching "capecitabine" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

38 results for “capecitabine” Back to intelligence hub

Search results

Page 2 of 2
  1. Capecitabine+Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stomach Neoplasms

    phase 2 small molecule terminated

    1 trial
  2. Capecitabine-Oxaliplatin-Irinotecan Combination

    The First People's Hospital of Lianyungang

    Unresectable Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial
  3. Cisplatin+Capecitabine+Sintilimab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  4. Mektovi film-coated tablets for metastatic colorectal cancer wi…

    Disc Medicine

    metastatic colorectal cancer with a proven RAS mutation after failure of standard systemic treatment regimens including at least 5- FU/capecitabine-oxaliplatin and irinotecan based standard treatment (unless contra-indications for either oxaliplatin or irinotecan)

    phase 2 small molecule active

    1 trial
  5. PCS6422 and capecitabine

    Processa Pharmaceuticals

    Breast Cancer

    phase 2 small molecule active

    1 trial
  6. TAR-0520 Gel

    Lacuna Pharma Pty Ltd

    Capecitabine-induced hand and foot syndrome

    phase 2 small molecule active

    1 trial
  7. TAX625

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Breast Cancer

    phase 2 small molecule active

    1 trial
  8. UC-GIG-2311

    Ningbo Cancer Hospital

    Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication

    phase 2 small molecule active

    1 trial
  9. capecitabine

    Cardiff Oncology

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial
  10. combination with Disitamab Vedotin and with Tislelizumab and Capecitabine

    Hospital Authority, Hong Kong

    Gastric Cancer

    phase 2 small molecule active

    1 trial
  11. PCS6422 and capecitabine

    Processa Pharmaceuticals

    Advanced Cancer

    phase 1 small molecule completed

    1 trial
  12. WX-UK1 in combination with Capecitabine

    United Therapeutics Europe Ltd

    Advanced Malignancies

    phase 1 small molecule completed

    1 trial
  13. standard dose capecitabine

    Karyopharm Therapeutics Inc

    Rectal Neoplasms

    phase 1 small molecule active

    1 trial
  14. OXALIPLATIN, CAPECITABINE

    Disc Medicine

    Locally advanced or metastatic gastro-intestinal carcinoma

    approved small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.